3 Buses and Auto Components Maker, Agrochemicals and Custom Manufacturing Company and Pharmaceutical Company Stocks With a Strong Future Roadmap: JBM Auto, PI Industries and Natco Pharma

Bus part, agrochemical and pharma stocks give investors a way to track businesses that sit close to everyday demand in India. JBM Auto, PI Industries and Natco Pharma cover a buses and auto components maker, an agrochemicals and custom manufacturing company and a pharmaceutical company.

This list covers three bus part, agrochemical and pharma stocks with complete current figures: JBM Auto, PI Industries and Natco Pharma. Every figure comes from the latest reported financials and the 9 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Bus Part, Agrochemical and Pharma Stocks?

Bus part, agrochemical and pharma stocks are listed companies that build buses and sheet metal parts for vehicles, make crop protection chemicals and custom manufactured intermediates, and develop specialty medicines including cancer therapies. Their earnings depend on vehicle orders, farm input demand and drug sales.

Bus Part, Agrochemical and Pharma Stocks at a Glance

On valuation, Natco Pharma trades at a P/E below the industry P/E, while JBM Auto and PI Industries trade above it, which reflects the growth the market already expects. Readers comparing bus part, agrochemical and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Bus Part, Agrochemical and Pharma Stocks Have a Strong Roadmap in India?

Bus part, agrochemical and pharma stocks have a strong roadmap in India because growing public transport needs, rising farm productivity requirements and steady demand for specialty medicines keep widening the market for these companies.

• Buses and parts. Cities add modern public transport.
• Agrochemicals. Farms need products to protect yields.
• Specialty pharma. Patients need advanced therapies.

Why JBM Auto Features Among These Bus Part, Agrochemical and Pharma Stocks

Among the bus part, agrochemical and pharma stocks on this list, JBM Auto makes sheet metal components, tooling, and buses, and is a significant supplier of electric buses and sheet metal parts to leading vehicle makers.

The company has a return on equity of 14.2%, a debt to equity ratio of 1.97 and a market capitalisation of Rs 12,533 crore. The stock trades at a P/E of 51.5, above the industry P/E of 36.9.

Revenue rose from Rs 3,214 crore in FY22 to Rs 6,227 crore in FY26, a compound annual growth rate of 18.0%. Net profit grew from Rs 156 crore in FY22 to Rs 238 crore in FY26, which works out to a compound annual growth rate of 11.1%. In the June 2026 quarter, revenue grew 13.9% year on year to Rs 1,474 crore, while net profit rose 13.4% to Rs 44.3 crore.

Roadmap: The company has secured large orders for electric buses under city transport programmes and supplies body and chassis components to passenger vehicle and commercial vehicle makers. Its manufacturing scale supports growth in both businesses.

What to watch: Track electric bus deliveries and the progress of orders under city bus programmes.

Why PI Industries Features Among These Bus Part, Agrochemical and Pharma Stocks

Among the vehicle, crop science and medicine shares on this list, PI Industries is a Udaipur-based agrochemical and custom synthesis company. It sells crop protection products in India and manufactures complex molecules for global innovators, and it has added pharma and specialty chemistry capabilities.

Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%.

The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P/E of 28.5, above the industry P/E of 23.3.

Roadmap: The company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.

What to watch: Check the growth of custom synthesis orders and new product launches.

Why Natco Pharma Features Among These Bus Part, Agrochemical and Pharma Stocks

Among the three companies on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.

Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.

The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.

Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.

JBM Auto vs PI Industries vs Natco Pharma on Key Financials

The table below sets the three bus part, agrochemical and pharma stocks side by side on revenue, profit and margin, using reported figures.

Natco Pharma posts the highest return on equity in this group at 15.4%. PI Industries has the largest FY26 revenue at Rs 7,024 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with bus part, agrochemical and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Bus Part, Agrochemical and Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these bus part, agrochemical and pharma stocks, the main points are: Long-term vehicle, crop science and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Order timing. Project awards can shift between periods.
• Season and monsoon. Crop protection sales follow rain and pest cycles.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter bus part, agrochemical and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Bus Part, Agrochemical and Pharma Stocks

Bus part, agrochemical and pharma stocks work best when investors track growth, valuation and return on equity side by side. JBM Auto, PI Industries and Natco Pharma each have a clear plan to grow. Based on the 9 November 2026 close, JBM Auto trades at Rs 499, PI Industries at Rs 1,750.7 and Natco Pharma at Rs 805.05.

Download the Univest iOS App or Univest Android App to track bus part, agrochemical and pharma stocks, set price alerts and get research-backed stock ideas.

What are bus part, agrochemical and pharma stocks?

Ans. Bus part, agrochemical and pharma stocks are listed companies that build buses and sheet metal parts for vehicles, make crop protection chemicals and custom manufactured intermediates, and develop specialty medicines including cancer therapies. Their earnings depend on vehicle orders, farm input demand and drug sales. This list looks at three of them, JBM Auto, PI Industries and Natco Pharma, using reported FY22 to FY26 financials and the 9 November 2026 closing prices.

Which bus part, agrochemical and pharma stocks are covered in this list?

Ans. This list covers JBM Auto, PI Industries and Natco Pharma. Based on the 9 November 2026 close, JBM Auto traded at Rs 499, PI Industries at Rs 1,750.7 and Natco Pharma at Rs 805.05. Their return on equity ranges from 11.8% to 15.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 21.0%.

Why do bus part, agrochemical and pharma stocks have a strong future roadmap in India?

Ans. Bus part, agrochemical and pharma stocks have a strong roadmap in India because growing public transport needs, rising farm productivity requirements and steady demand for specialty medicines keep widening the market for these companies. The main drivers are as follows. Buses and parts. Cities add modern public transport. Agrochemicals. Farms need products to protect yields. Specialty pharma. Patients need advanced therapies. Together these factors give the companies on this list a visible path for growth over the coming years.

How has JBM Auto performed financially?

Ans. Revenue rose from Rs 3,214 crore in FY22 to Rs 6,227 crore in FY26, a compound annual growth rate of 18.0%. Net profit grew from Rs 156 crore in FY22 to Rs 238 crore in FY26, which works out to a compound annual growth rate of 11.1%. In the June 2026 quarter, revenue grew 13.9% year on year to Rs 1,474 crore, while net profit rose 13.4% to Rs 44.3 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 1.97 and a market capitalisation of Rs 12,533 crore. The stock trades at a P/E of 51.5, above the industry P/E of 36.9. Looking ahead, the company has secured large orders for electric buses under city transport programmes and supplies body and chassis components to passenger vehicle and commercial vehicle makers. Its manufacturing scale supports growth in both businesses.

How has PI Industries performed financially?

Ans. Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%. The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P/E of 28.5, above the industry P/E of 23.3. Looking ahead, the company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.

How has Natco Pharma performed financially?

Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What risks should investors check before buying bus part, agrochemical and pharma stocks?

Ans. Investors should check a few risks before buying bus part, agrochemical and pharma stocks. Order timing. Project awards can shift between periods. Season and monsoon. Crop protection sales follow rain and pest cycles. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of bus part, agrochemical and pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 9 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.